南模生物(688265) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥72,706,319.65, representing a year-on-year increase of 33.88%[4] - The net profit attributable to shareholders was ¥13,921,971.48, reflecting a year-on-year growth of 17.64%[4] - Total operating revenue for Q1 2022 was ¥72,706,319.65, an increase of 33.9% compared to ¥54,305,590.46 in Q1 2021[17] - Net profit for Q1 2022 reached ¥13,921,971.48, representing a 17.6% increase from ¥11,834,124.97 in Q1 2021[18] - The company reported a total comprehensive income of ¥13,903,726.09 for Q1 2022, compared to ¥11,834,124.97 in Q1 2021[19] Research and Development - R&D investment totaled ¥11,443,479.93, which is an increase of 36.37% compared to the previous year, indicating enhanced R&D capabilities[4][7] - Research and development expenses in Q1 2022 amounted to ¥11,443,479.93, a significant rise of 36.5% compared to ¥8,391,567.71 in Q1 2021[18] - The proportion of R&D investment to operating revenue was 15.74%, an increase of 0.29 percentage points[5] Cash Flow and Liquidity - The net cash flow from operating activities was -¥20,580,327.50, a significant decrease of 803.37% year-on-year, primarily due to slower customer payment speeds and increased operational expenses[4][7] - The total cash inflow from operating activities for Q1 2022 was ¥50,345,556.32, a decrease of 9.4% compared to ¥55,275,599.11 in Q1 2021[21] - The net cash outflow from operating activities was ¥20,580,327.50, contrasting with a net inflow of ¥2,925,966.01 in the same period last year[21] - The ending balance of cash and cash equivalents was ¥256,106,060.25, a decrease from ¥64,618,665.71 in the same quarter last year[22] - The cash flow from operating activities was negatively impacted by increased payments to employees, which rose to ¥35,398,217.71 from ¥28,191,409.02 in Q1 2021[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,942,015,807.46, a decrease of 1.12% from the end of the previous year[5] - The company's total assets as of Q1 2022 were ¥1,942,015,807.46, slightly down from ¥1,964,057,227.03 in the previous quarter[15] - Total liabilities decreased to ¥153,430,872.61 in Q1 2022 from ¥180,396,846.80 in Q1 2021[15] - The company's equity attributable to shareholders increased to ¥1,788,584,934.85 in Q1 2022, compared to ¥1,783,660,380.23 in Q1 2021[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,277[9] - The company’s major shareholders include various investment funds, with significant holdings in common stock[11] - The report indicates that the company has not received any declarations of related party transactions among shareholders, maintaining transparency[11] Operational Challenges - The company is facing operational challenges due to COVID-19, impacting logistics and client operations, which may affect future performance[12] - The company has implemented measures to mitigate the impact of the pandemic on its operations, ensuring production continuity[12] Earnings Per Share - Basic earnings per share (EPS) decreased by 10.00% to ¥0.18, while diluted EPS remained unchanged at ¥0.18[4] - The basic earnings per share for Q1 2022 was ¥0.18, down from ¥0.20 in Q1 2021[19]